Twenty years of participation of racialised groups in type 2 diabetes randomised clinical trials: a meta-epidemiological review
Authors' conclusion
Racialised participants are under-represented in government- and industry-funded type 2 diabetes trials. Strategies to improve recruitment and enrolment of racialised participants into RCTs should be developed.
Study context
- Population
- RCTs of T2D pharmacotherapies (≥100 adult participants with T2D) in select medical journals, Ovid MEDLINE 1 January 2000 to 31 December 2020
- Participants
- 283,122 participants83 trials
- Comparison
- Government-funded vs industry-funded T2D RCTs: participation of white and racialised participants
- Outcome
- Participation-to-prevalence ratio (PPR) for white and racialised participants (PPR <0.80 under-representation; >1.20 over-representation)
Methodological detailsRisk of bias assessments not conducted
- Risk of bias assessments not conducted
Pooled result
As reported in the abstract
Pooled PPR
| Group | Participation-to-prevalence ratio (PPR), white participants | PPR, racialised participants |
|---|---|---|
| Government-funded | 1.11 (95% CI 0.99, 1.24) | 0.72 (95% CI 0.60, 0.86) |
| Industry-funded | 1.95 (95% CI 1.74, 2.18) | 0.36 (95% CI 0.32, 0.42) |
Participation-to-prevalence ratio (PPR), white participants
Government-funded1.11 (95% CI 0.99, 1.24)
Industry-funded1.95 (95% CI 1.74, 2.18)
PPR, racialised participants
Government-funded0.72 (95% CI 0.60, 0.86)
Industry-funded0.36 (95% CI 0.32, 0.42)
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Twenty years of participation of racialised groups in type 2 diabetes randomised clinical trials: a meta-epidemiological review. Diabetologia. Published 4 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →